A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
about
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
P2860
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@en
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@nl
type
label
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@en
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@nl
prefLabel
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@en
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@nl
P2093
P2860
P356
P1476
A novel flow cytometric assay ...... mphoma post anti-CD19 therapy.
@en
P2093
Brent L Wood
Jonathan R Fromm
Katy Dougherty
Sindhu Cherian
Valerie Miller
Vivian McCullouch
P2860
P304
P356
10.1002/CYTO.B.21482
P577
2016-09-06T00:00:00Z